Acadia Pharmaceuticals Gets European Approval of Rett Syndrome Drug Daybu
Dow Jones
Yesterday
Acadia Pharmaceuticals has won European Commission approval for its Daybu as a treatment for neurobehavioral symptoms of Rett syndrome in patients five and older.
Acadia on Monday said the green light makes Daybu the first and only treatment approved in the European Union for Rett syndrome, a rare neurodevelopmental disorder.
The San Diego drugmaker said it will now begin pricing and reimbursement negotiations with relevant national authorities across the EU.
Acadia, which markets Daybu as Daybue in the U.S. and Canada, earlier this month said it expects global net product sales of the drug to reach $480 million to $510 million this year.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.